We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Siemens Healthineers - Laboratory Diagnostics

Provides advanced laboratory diagnostics solutions for the medical industry read more Featured Products: More products

Download Mobile App

Compact Immunoassay and Clinical Chemistry Analyzer Helps Low- to Mid-Volume Labs Tackle Challenges

By LabMedica International staff writers
Posted on 21 Jul 2023
Print article
Image: The Atellica CI Analyzer offers the highest throughput in the smallest footprint (Photo courtesy of Siemens)
Image: The Atellica CI Analyzer offers the highest throughput in the smallest footprint (Photo courtesy of Siemens)

Clinical laboratories face crucial operational challenges that hinder productivity, such as an increased number of patient samples, staff shortages, and additional documentation requirements. Now, a new immunoassay and clinical chemistry testing system is designed to address these issues related to labor shortages, while also promoting revenue growth and enhancing agility beyond standardization and clinical equivalence. Workflow improvements offered by this system can aid laboratories in achieving more predictable turnaround times, reducing reporting duties, and allowing staff to concentrate on essential lab operations.

Every lab, irrespective of its size, grapples with significant challenges arising from labor shortages. These range from ensuring reliable test results to facilitating predictable care, protecting staff, securing data, and achieving environmental objectives. The Atellica CI Analyzer from Siemens Healthineers (Erlangen, Germany) enables both standalone labs and satellite labs of wider health networks to access the same reagents, consumables, and intelligent software as the company's flagship Atellica Solution, but now in a compact 1.9 square meters footprint ideal for smaller laboratories. Labs with low to medium testing volumes will appreciate the competitive edge offered by the Atellica CI Analyzer, including improved turnaround time predictability, advanced reporting functionality, and robust safety and security measures.

Designed with standout capabilities, the Atellica CI Analyzer maximizes downtime usage and bolsters lab efficiency and profitability. Features like random access sampling, micro-volume aspiration, and automatic scheduling for maintenance and quality control enable labs to deliver more predictable sample turnaround times. The independent operation of chemistry and immunoassay engines ensures that throughput isn't compromised if one of the two needs to be halted. In addition to producing patient results, labs also need to meet reporting requirements, address cybersecurity, and achieve staff satisfaction goals. The Atellica CI Analyzer comes with the Atellica Laboratory Evaluation Suite to provide inspection-ready reports, helping labs meet accreditation guidelines without requiring additional software and allowing laboratory staff to redirect their efforts toward other important lab operations. Increased security measures are also available, including user authentication, role-based authorizations, and audit trails. With a planned menu of over 200 assays spanning 20 disease states, each lab in a health network can select the best tests for its patient population, fulfilling clinical needs that might otherwise be unmet. More than 50 key assays can produce results in less than 14 minutes.

"Workflow standardization and clinical equivalence are critical components of a successful laboratory operation within a health network. The Atellica CI Analyzer elevates laboratory operations to a new level of agility," said Sharon Bracken, head of Diagnostics for Siemens Healthineers. "Labs today need testing instrumentation and informatics that can easily keep pace with rapidly changing testing demands as they occur. This next-generation laboratory analyzer anticipates workflow bottlenecks, mitigates them proactively, and delivers insights based on data that help laboratory staff do their job more effectively and efficiently."

Related Links:
Siemens Healthineers 

Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
All-in-one Molecular Diagnosis System
Panall 8000

Print article


Molecular Diagnostics

view channel
Image: Protein ‘signatures’ obtained via a blood sample can be used to predict the onset of 67 diseases (Photo courtesy of Queen Mary University of London)

Protein Signatures in Blood Can Predict Risk of Developing More Than 60 Diseases

Measuring specific proteins to diagnose conditions like heart attacks, where troponin is tested, is a well-established clinical practice. Now, new research highlights the broader potential of protein measurements... Read more


view channel
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide.... Read more


view channel
Image: The Simplexa C. auris direct kit is a real-time polymerase chain reaction assay run on the LIAISON MDX instrument (Photo courtesy of Diasorin)

Novel Molecular Test to Help Prevent and Control Multi Drug-Resistant Fungal Pathogen in Healthcare Settings

Candida auris (C. auris) is a rapidly emerging multi drug-resistant fungal pathogen that is commonly found in healthcare environments, where it presents a challenge due to its ability to asymptomatically... Read more


view channel
Image: The tool can improve precision oncology by accurately predicting molecular subtypes and therapy responses (Photo courtesy of Shutterstock)

Computational Tool Integrates Transcriptomic Data for Improved Breast Cancer Diagnosis and Treatment

Breast cancer is the most commonly diagnosed cancer globally, presenting in various subtypes that require precise identification for effective, personalized treatment. Traditionally, cancer subtyping has... Read more


view channel
Image: Beckman Coulter will utilize the ALZpath pTau217 antibody to detect key biomarker for Alzheimer\'s disease on its DxI 9000 immunoassay analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter Licenses Alzpath's Proprietary P-tau 217 Antibody to Develop Alzheimer's Blood Test

Cognitive assessments have traditionally been the primary method for diagnosing Alzheimer’s disease, but this approach has its limitations as symptoms become apparent only after significant brain changes... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.